`
`2000
`
`[A]
`
`2001
`
`[B]
`
`2002
`
`[C]
`
`2003
`
`[D]
`
`2004
`
`[E]
`
`2005
`
`[F]
`
`2006
`
`[G]
`
`2007
`
`[H]
`
`48.0%
`
`4,287.0
`
`324.0
`n/a
`n/a
`n/a
`24.0%
`
`2,148.0
`
`179.0
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`26.0%
`
`2,341.0
`41.0
`
`10.0
`
`
`
`554.0
`
`$
`
`$
`
`$
`
`$
`$
`$
`
`31.0%
`
`4,255.0
`
`310.0
`17.0%
`
`2,370.0
`
`178.0
`23.0%
`
`3,215.0
`
`240.0
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`17.0%
`
`2,400.0
`
`36.0
`
`25.0
`
`
`789.0
`
`$
`
`$
`
`$
`
`$
`$
`$
`
`15.0%
`
`2,269.0
`
`185.0
`34.0%
`
`5,096.0
`
`395.0
`26.0%
`
`3,890.0
`
`305.0
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`17.0%
`
`2,542.0
`
`33.0
`
`19.0
`
`
`937.0
`
`$
`
`$
`
`$
`$
`$
`
`$
`
`$
`
`$
`
`$
`
`8.0%
`
`1,199.0
`
`102.0
`40.0%
`
`6,382.0
`
`545.0
`28.0%
`
`4,512.0
`
`379.0
`n/a
`n/a
`n/a
`2.0%
`
`331.0
`
`23.0
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`14.0%
`
`2,161.0
`
`28.0
`
`18.0
`
`
`$
`$
`1,095.0$
`
`$
`
`$
`
`$
`
`$
`
`$
`
`5.0%
`
`734.0
`
`90.0
`40.0%
`
`5,873.0
`
`690.0
`21.0%
`
`3,150.0
`
`400.0
`n/a
`n/a
`n/a
`4.0%
`
`533.0
`
`39.0
`1.0%
`
`76.0
`8.0
`
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`17.0%
`
`2,500.0
`
`30.0
`
`28.0
`
`
`$
`$
`1,285.0$
`
`$
`
`$
`
`$
`
`$
`
`$
`
`$
`
`$
`
`4.0%
`
`780.0
`
`67.0
`40.0%
`
`7,016.0
`
`608.0
`20.0%
`
`3,562.0
`
`375.0
`2.0%
`
`385.0
`
`35.0
`3.0%
`
`492.0
`
`42.0
`2.0%
`
`354.0
`
`30.0
`n/a
`n/a
`n/a
`3.0%
`
`459.0
`45.0
`
`15.0%
`2,654.0
`
`
`30.0
`
`30.0
`
`
`$
`$
`1,262.0$
`
`$
`
`$
`
`$
`
`$
`
`$
`
`$
`
`$
`
`4.0%
`
`597.0
`
`72.0
`42.0%
`
`6,915.0
`
`793.0
`16.0%
`
`2,662.0
`
`322.0
`7.0%
`
`1,104.0
`
`118.0
`3.0%
`
`441.0
`
`43.0
`n/a
`n/a
`n/a
`2.0%
`
`389.0
`37.0
`
`8.0%
`
`1,297.0
`
`144.0
`17.0%
`
`2,835.0
`
`54.0
`2.0
`
`
`
`$
`$
`1,585.0$
`
`$
`
`$
`
`$
`
`$
`
`$
`
`$
`
`$
`
`3.0%
`
`509.0
`
`62.0
`39.0%
`
`6,776.0
`
`800.0
`2.0%
`
`362.0
`
`52.0
`9.0%
`
`1,539.0
`
`150.0
`2.0%
`
`395.0
`
`35.0
`n/a
`n/a
`n/a
`2.0%
`
`429.0
`
`50.0
`12.0%
`
`2,065.0
`
`245.0
`30.0%
`
`5,238.0
`
`100.0
`
`-
`
`
`$
`$
`1,494.0$
`
`Drug
`
`Detrol
`
`Detrol LA
`
`Ditropan XL
`
`Enablex
`
`Oxytrol
`
`Sanctura
`
`Sanctura/XR
`
`Vesicare
`
`Generic oxybutynin
`
`Other
`Total
`
`Metric
`
`Market share
`Prescriptions
`Sales
`Market share
`Prescriptions
`Sales
`Market share
`Prescriptions
`Sales
`Market share
`Prescriptions
`Sales
`Market share
`Prescriptions
`Sales
`Market share
`Prescriptions
`Sales
`Market share
`Prescriptions
`Sales
`Market share
`Prescriptions
`Sales
`Market share
`Prescriptions
`Sales
`Sales
`Sales
`
`Notes and sources
`Prescriptions are in thousands Sales are in millions of $U S
`[A] Cowen and Company, "Therapeutic Categories Outlook," 10/2001, at 301
`[B] Cowen and Company, "Therapeutic Categories Outlook," 10/2002, at 366
`[C] Cowen and Company, "Therapeutic Categories Outlook," 10/2003, at 434
`[D] Cowen and Company, "Therapeutic Categories Outlook," 3/2004, at 522
`[E] Cowen and Company, "Therapeutic Categories Outlook," 10/2005, at 664
`[F] Cowen and Company, "Therapeutic Categories Outlook," 10/2006, at 804
`[G] Cowen and Company, "Therapeutic Categories Outlook," 10/2007, at 1020
`[H] Cowen and Company, "Therapeutic Categories Outlook," 9/2008, at 1155
`
`Petitioner Alembic Pharmaceuticals Limited - Exhibit 1039 - Page 1